Updated: May 24, 2026

High Content Screening in Neurodegenerative Diseases
Published on: January 6, 2012
Punita Sharma1, D Michael Ando, Aaron Daub
1Gladstone Institute of Neurological Disease, San Francisco, California, USA.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Developing novel therapeutics for neurodegenerative diseases like Alzheimer's and Parkinson's requires advanced screening. Our high-throughput screening (HTS) in primary neurons offers a biologically relevant approach to accelerate drug discovery.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: